Lotensin Hct Tablet
NDC Package 30698-452-01
Package Information
Lotensin Hct (benazepril hydrochloride and hydrochlorothiazide) tablets is a medication a combination of two drugs, an ACE inhibitor (benazepril) and a "water pill"/diuretic (hydrochlorothiazide). This formulation utilizes a tablet delivery system. Marketed by Validus Pharmaceuticals Llc, this product is identified by NDC 30698-452 and is authorized under FDA application NDA020033.
Identification & Billing
- RxCUI: 898362 - benazepril HCl 10 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
- RxCUI: 898362 - benazepril hydrochloride 10 MG / hydrochlorothiazide 12.5 MG Oral Tablet
- RxCUI: 898362 - benazepril hydrochloride 10 MG / HCTZ 12.5 MG Oral Tablet
- RxCUI: 898362 - BZP hydrochloride 10 MG / HCTZ 12.5 MG Oral Tablet
- RxCUI: 898366 - Lotensin HCT 10 MG / 12.5 MG Oral Tablet
Clinical Specifications
- Angiotensin Converting Enzyme Inhibitor - [EPC] (Established Pharmacologic Class)
- Angiotensin-converting Enzyme Inhibitors - [MoA] (Mechanism of Action)
- Decreased Blood Pressure - [PE] (Physiologic Effect)
- Increased Diuresis - [PE] (Physiologic Effect)
- Thiazide Diuretic - [EPC] (Established Pharmacologic Class)
- Thiazides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 30698 - Validus Pharmaceuticals Llc
- 30698-452 - Lotensin Hct
- 30698-452-01 - 100 TABLET in 1 BOTTLE
- 30698-452 - Lotensin Hct
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 30698-452-01 identifies a specific commercial package of 100 tablet in 1 bottle of Lotensin Hct, a human prescription drug labeled by Validus Pharmaceuticals Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This tablet is formulated for oral use and contains benazepril hydrochloride; hydrochlorothiazide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Validus Pharmaceuticals Llc on May 30, 1992. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is a combination of two drugs, an ACE inhibitor (benazepril) and a "water pill"/diuretic (hydrochlorothiazide). It is used to treat high blood pressure (hypertension). Benazepril works by relaxing blood vessels, causing them to widen. The hydrochlorothiazide diuretic increases the amount of urine you make, therefore decreasing excess water and salt in your body. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
How is this Validus Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 30698045201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.